Login to Your Account



Other News To Note


Friday, March 16, 2012
• InterMune Inc., of Brisbane, Calif., said Germany's reimbursement body granted the additional benefit of Esbriet (pirfenidone) in adults for mild to moderate idiopathic pulmonary fibrosis, classifying the drug's additional benefit as Stage IV, or not quantifiable. That designation "takes the worst-case scenario off the table," noted Wells Fargo analyst Brian Abrahams, and positions the firm "reasonably for upcoming pricing negotiations." Esbriet won European approval a year ago. The company is conducting another pivotal trial for FDA approval.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription